Porcine adenovirus-3 (PAV-3) was developed as an expression vector using homologous recombination in Escherichia coli BJ 5183. As a prerequisite, the complete genome of PAV-3 was first introduced as a PacI restriction fragment into a bacterial plasmid. The plasmid, when PacI restricted and transfected into swine testicular cells, produces an infectious virus. The potential of this procedure was demonstrated by the construction of several PAV-3 recombinants. Part of the E3 region, which is nonessential for virus replication under cell culture conditions, was identified and deleted from the virus genome. The gene for glycoprotein D (gD) of pseudorabies virus (PRV), which elicits PRV-neutralizing antibodies in pigs, was cloned and expressed from the E3 region of PAV-3. A 50 kDa polypeptide was identified in recombinant PAV-3-infected cell lysates by immunoprecipitation assays using gD-specific monoclonal antibodies. In another experiment, a region between the right inverted terminal repeat and the promoter of the E4 region was used to clone and express the chloramphenicol acetyltransferase (CAT) gene under the control of SV40 immediate early promoter. CAT gene expression was observed irrespective of the orientation of the CAT gene. These results indicate that the helper-independent recombinant PAV-3 could be used as an expression vector and has potential as a recombinant vaccine vector in pigs.
Introduction
Adenoviruses are double-stranded DNA viruses which infect a wide variety of mammals and birds (Ishibashi & Yasue, 1984) . Several strains have been isolated from pigs and are currently classified into five serotypes (Derbyshire et al., 1975 ; Hirahara et al., 1990) . The proposed use of porcine adenoviruses (PAVs) as viral vaccine vectors (Tuboly et al., 1993) for the induction of mucosal immune responses against enteric viral antigens in pigs has generated great interest in understanding the molecular biology of these viruses. PAV-3 was chosen as a candidate vector based on its low virulence and the ability to grow to high titres in cell culture (Derbyshire et al., 1975 ; Hirahara et al., 1990 ). The prototype strain (6618) of this virus was first isolated from a rectal swab collected from a healthy piglet (Clarke et al., 1967) , and experimental infections of piglets with PAV-3 are subclinical or associated with transient diarrhoea (Derbyshire et al., 1975) . A prerequisite for Author for correspondence : P. Seshidhar Reddy.
Fax j1 306 966 7478. e-mail reddys!sask.usask.ca the development of PAV-3 as an expression vector was molecular characterization of the genome. As steps towards that goal, cloning and physical mapping of the DNA (Reddy et al., 1993) , nucleotide sequence analysis of the E1, E3 and E4 regions and inverted terminal repeats (ITRs) (Reddy et al., a, b, 1996 (Reddy et al., , 1997 , and of a few late region genes (McCoy et al., a, b, 1997 of PAV-3 have been completed. Recently, determination of the complete nucleotide sequence and transcription map of the genome has indicated that the genetic organization in PAV-3 is collinear to that of human adenoviruses (HAVs) .
Recombinant HAVs are being used as expression vectors in in vivo and in vitro. Large-scale use of HAV-based vectors as live recombinant vaccines in animals and humans has been hampered for a number of reasons. Several serotypes of HAVs were shown to replicate in cells of animal origin and therefore it is very likely that these viruses might cross species barriers when used under field conditions. Furthermore, pre-existing humoral and cellular immune responses in humans may interfere with the replication of recombinant adenoviruses, and complementation\recombination between replication-defective recombinant HAVs and wild-type HAVs that are in 0001-5931 # 1999 SGM FGD circulation could lead to infection and disease. Animal adenoviruses are highly species specific and can enter human cells but do not replicate (Mittal et al., 1995 ; Klonjkowski et al., 1997) . Animal adenoviruses also do not encounter the problem of pre-existing immune responses in humans and thus have great potential as gene transfer vectors. In addition, these vectors could be used as live viral vaccines in animals (Xu et al., 1997 ; Sheppard et al., 1998 ; Zakhartchouk et al., 1998) .
The classical method of generating recombinant adenoviruses involves recombination between a transfer vector and the viral DNA in transfected cells. This method generates a background of non-recombinant viruses and the recombinant of interest must be plaque purified. The preparation of viral DNA from infected cells is relatively expensive and difficult. To circumvent these problems Bett et al. (1994) developed a two-plasmid system to generate recombinant adenoviruses. This method is also not very efficient in generating recombinant adenoviruses as it depends on recombination in transfected cells, which occurs at a very low frequency. Recently, homologous recombination in Saccharomyces cerevisiae was utilized to construct recombinant adenoviral genomes by a two-step gene replacement procedure (Ketner et al., 1994) . This method of generating recombinants involves cloning of the complete viral genome into a yeast artificial chromosome (YAC). It requires linearization of adenoviral DNA at a site where the recombination is targeted, which is sometimes difficult due to the large size of the DNA. More recently, an E. coli recombination system was developed by Chartier et al. (1996) to generate recombinant adenoviruses and was found to be highly efficient and simple. This procedure takes advantage of the highly efficient homologous recombination system in E. coli BJ 5183. When compared with the YAC system, the E. coli system has several advantages such as higher growth rates, relatively simple transformation protocols, gives more plasmid DNA and generates DNA with a higher transfection efficiency (Chartier et al., 1996) . The objective of this study was to adopt the E. coli recombination system to develop PAV-3 as an expression vector and to find out whether commonly used insertional sites of adenoviruses could be used to develop replication-competent PAV-3-based vectors.
Methods
Virus and viral DNA. The 6618 strain of PAV-3 was propagated in a swine testis (ST) cell line or a transformed foetal porcine retina cell line (VIDO R1). The cells were grown in MEM supplemented with 10 % foetal bovine serum (FBS). The viral DNA was extracted either from infected cell monolayers by the method of Hirt (1967) or from purified virions as described by Graham & Prevec (1991) .
Construction of full-length infectious clone of PAV-3. All recombinant DNA molecules were constructed by standard cloning methods and propagated in E. coli DH5α unless otherwise stated. Figs 1 and 2 summarize the strategy used for construction of plasmids used in the study. Plasmid p3SB (Reddy et al., 1993) , containing the left end of the PAV-3 genome (position 1-8870), was used for amplification of the first 433 bp of the genome in PCR using oligonucleotides 1 (5' GCGGATC-CTTAATTAACATCATCAATAATATACCGCACACTTTT 3') and 2 (5' CACCTGCAGATACACCCACACACGTCATCTCG 3'), where the adenoviral sequences are shown in bold and the engineered restriction enzyme sites are italicized. The amplified PCR product harbours the left ITR and the packaging signal. Plasmid p3SA (Reddy et al., 1993) contains the right end of the PAV-3 genome and was used as a template in PCR for amplification of the terminal 573 bp of the genome using oligonucleotides 1 and 3 (5' CACCTGCAGCCTCCTGAGTGTGAAGA-GTGTCC 3'). The primers were designed based on nucleotide sequence information described elsewhere (Reddy et al., , 1997 . The PCR product obtained with oligonucleotides 1 and 2 was digested with BamHI and PstI and the product obtained using primers 1 and 3 was digested with PstI and PacI. Modified bacterial plasmid pPolyIIsn14 (Chartier et al., 1996) was digested with BamHI and PacI. The PCR products were cloned into the plasmid by three-way ligation to generate plasmid pPAV-100, which carries both termini of PAV-3 bordered by PacI sites. Plasmid pFPAV-200, which contains the full-length PAV-3 genome, was generated by co-transformation of E. coli BJ 5183 recBC sbcBC (Chartier et al., 1996) with PstI-linearized pPAV-100 and the genomic DNA of wild-type PAV-3 (Fig. 1 a) . To determine the infectivity of pFPAV-200, the plasmid was digested with PacI and transfected into ST cells.
Construction of transfer vectors and recombinant adenoviruses.
The gene encoding green fluorescent protein (GFP) without any transcription control elements obtained from pGREEN LANTERN-1 (GIBCO BRL) by NotI digestion was blunt-end repaired and cloned into the SacI (nucleotide 27789) and SnaBI sites (nucleotide 28710) present in a cloned KpnI-BamHI fragment of the genome. This fragment represents the PAV-3 genome from nucleotides 26716 to 31064 cloned into pGEM-3Z (Promega). The KpnI-BamHI fragments encompassing the modified E3 regions were isolated from the plasmids and individually recombined in E. coli BJ 5183 with pFPAV-200, which was previously linearized at nucleotide position 28710 by SnaBI digestion.
To delete part of the E3 region, the PAV-3 genome between nucleotides 27402 and 28112 was amplified with Pfu DNA polymerase (Stratagene) using primer 1 (5' GACTGACGCCGGCATGCAAT 3') and primer 2 (5' CGGATCCTGACGCTACGAGCGGTTGTA 3'). In the second PCR, the genomic region between nucleotides 28709 and 29859 was amplified using primer 3 (5' CGGATCCATACGTACAGATGA-AGTAGC 3') and primer 4 (5' TCTGACTGAAGCCGACCTGC 3'). BamHI recognition sequences were engineered into primers 2 and 3. The product obtained in the first PCR was digested with BamHI and gel purified. The second PCR product was digested with BamHI and SpeI and also gel purified. The two gel-purified fragments were cloned into SpeI-SmaI sites of plasmid pBluescript SK(j) by three-way ligation ( Fig.  1 b) The resulting plasmid was named pPAV-300 and contains the PAV-3 genome between nucleotides 27402 and 29859 with a deletion of the E3 region between nucleotides 28113 and 28708. An 1868 bp SphI-SpeI fragment spanning the modified E3 region was isolated from pPAV-300 and was rescued into pFPAV-200 by homologous recombination in E. coli to create plasmid pFPAV-300 ( Fig. 1 c) . To construct a recombinant PAV-3 expressing pseudorabies virus (PRV) gD, the gene without any flanking regulatory sequences obtained from pSLgD was cloned into the SnaBI site of pPAV-300 in the same orientation as the E3 transcription unit, creating plasmid pPAV-300-gD. A SphI-SpeI fragment obtained from this plasmid was used to generate a full-length clone with the E3 region deleted and containing the gD gene (pFPAV-300-gD) by homologous recombination in BJ 5183 (Fig. 2 a) .
To clone and express the chloramphenicol acetyltransferase (CAT) gene from a site near the right end of the genome, the cloned rightterminal fragment (31054-34094) generated by XhoI was used as a transfer vector (pPAV400). The CAT gene under the control of the SV40 immediately early promoter and SV40 polyadenylation signal obtained from pCAT-promoter vector (Promega) by BglII and BamHI digestion was blunt-ended with the Klenow fragment of DNA polymerase I. The fragment was purified by gel electrophoresis and inserted into a unique HpaI site (nucleotide position 33848) of pPAV400 in both orientations. Plasmid pFPAV-400-CAT2 has a CAT gene in the same orientation as the E4 transcription unit and pFPAV-400-CAT6 carries the same gene in the opposite orientation. The fragments containing the CAT gene were rescued into the full-length plasmid by homologous recombination in E. coli between the isolated terminal fragments and HpaI-restricted pFPAV-200 (Fig. 2 b) .
Transfections. Monolayers of ST cells grown in a six-well dish were transfected with various full-length constructs using Lipofectin (GIBCO BRL) according to the manufacturer's recommendations. Prior to transfection, linear recombinant genomes were released from the plasmid by digestion with PacI. The genome structures of the resultant viruses were confirmed by restriction enzyme analysis.
Immunopreciptation. Confluent monolayers of ST cells in six-well dishes were infected with wild-type PAV-3 or recombinant PAV-3 at an m.o.i. of 5. The cells were preincubated for 2 h in MEM lacking methionine and cystine prior to labelling with 50 µCi [$&S]methionine\ cysteine [Tran$&S label, ICN (1000 Ci\mmol)] for 4 h. The cells were washed once with PBS, harvested by scraping and then lysed with icecold modified radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 8n0, 150 mM NaCl, 1 % sodium deoxycholate, 1 % NP40, 0n1 % SDS, 1 mM PMSF). The radiolabelled protein was immunoprecipitated with anti-PRV gp50 monoclonal antibodies (Wathen & Wathen, 1984) and analysed by SDS-PAGE. The gels were dried and protein bands were visualized by autoradiography.
Southern blot hybridization. The DNA fragments of various recombinant plasmids of PAV-3 were transferred from agarose gels to Nytran membranes (Schleicher and Schuell) as described (Reddy et al., 1993) . The genes encoding PRV gD and CAT were labelled with [$#P]dCTP by the random primer labelling technique. Hybridizations were carried out at 42 mC in the presence of 50 % formamide. Prehybridization, hybridizations and washing of membranes were carried out as described (Reddy et al., 1993) .
CAT assays. CAT activity was monitored by liquid scintillation counting of CAT reaction products using a CAT enzyme assay kit supplied by Promega. Briefly, the cell extracts obtained at different times post-infection were incubated in a reaction mix containing ["%C]-chloramphenicol and n-butyryl-coenzyme A. The reaction products were extracted with xylene and the xylene phase mixed with scintillant and counted in a scintillation counter. the E3 region. By PCR, the PAV-3 genome between nucleotides 27402 and 28122, and 28709 and 29859, was amplified using primers 1 and 2, and 3 and 4, respectively. The amplified products were cloned into pBluescript to generate pPAV-300. 
Results

Construction of a full-length infectious clone of PAV-3
The complete genome of PAV-3 was cloned into a bacterial plasmid, pPolyIIsn, by homologous recombination between PstI-restricted pPAV-100 and the genomic DNA of wild-type PAV-3. Plasmid pPAV100 contains 433 and 573 bp of PAV-3 DNA from the left and right ends of the genome, respectively, amplified by PCR. Two unique PacI sites were engineered immediately upstream of the left ITR and immediately downstream of the right ITR into the PCR products. As there are no PacI recognition sequences in the genome of PAV-3, the introduction of PacI sites at both ends of the ITR allows precise excision of full-length adenoviral genome from pFPAV-200. Moreover, PacI recognizes an 8-mer nucleotide sequence and hence it is very rare for a foreign gene of interest to have this cleavage site. Following cotransformation of BJ 5183 with PstIlinearized pPAV-100 and the wild-type PAV-3 genomic DNA more than 100 ampicillin-resistant colonies were obtained. Four colonies were randomly picked and the miniprep DNA from these colonies was used to transform competent E. coli DH5α. The reason for choosing DH5α is that the yield of plasmid DNA from BJ 5183 was very low. The plasmid DNA extracted from E. coli DH5α was used for restriction enzyme analysis. Restriction enzyme analysis with several enzymes of the DNA from four clones gave an identical pattern, which was expected for plasmids containing the complete PAV-3 genome. The next step involved checking the infectivity of the fulllength plasmids. This was achieved by transfection of ST cells with 2-3 µg of PacI-restricted pFPAV-200. All four clones were found to be infectious with viral plaques seen as early as 7 days after transfection. The viruses recovered after transfection were cultivated on ST cells. The viral DNA was extracted from infected cells by Hirt (1967) method and subjected to restriction enzyme analyses. The viruses derived from pFPAV-200 gave a restriction enzyme pattern that was indistinguishable from that of wild-type viral DNA (data not shown).
Construction of E3 deletion mutants
In HAVs (Berkner, 1988) , bovine adenovirus-3 (BAV-3 ; Mittal et al., 1995 ; Zakhartchouk et al., 1998) and BAV-1 (Evans et al., 1998) , the proteins produced from the E3 region are nonessential for virus replication in cell culture. To increase the vector capacity of replication-competent adenoviral vectors, compensatory deletions are mostly made in the E3 region. To identify the extent of deletions that could be made in the E3 region of PAV-3, the gene encoding GFP without any flanking regulatory sequences was inserted into two different parts of the region. Blunt-ended SacI and SnaBI sites present in the E3 region were used to insert the GFP in the same orientation as the E3 transcription unit. The KpnI-BamHI fragment containing the modified E3 region was gel-purified and rescued into a full-length clone by homologous recombination. Virus could only be obtained with a full-length construct that had the GFP gene cloned into the SnaBI (PAV-3-GFP2) site, indicating that the open reading frame of E3 where the SacI site is located may be required for virus replication. By utilizing a PCR approach, 595 bp of the E3 region was deleted from the E3 transfer vector and was introduced into pFPAV-200 using recombination in E. coli to generate plasmid pFPAV-300 (Fig. 1 b) . A virus with such a deletion (PAV-3 E3) was obtained following transfection of ST cells with PacI-restricted pFPAV-300. The SalI restriction pattern of viral DNA was analysed and was as expected for a virus with the E3 deletion (Fig. 3 a, lane 5) . Reduction in size and the resulting increase in mobility of the top band in lane 5 relative to the corresponding band of wild-type virus in lane 4 was due to the deletion created in the E3 region. The E3 deletion mutant was able to replicate in cells to higher titres than that obtained with wild-type PAV-3 (see Fig. 6 ).
Construction of E3 deletion-based recombinants
To construct a recombinant adenovirus expressing gD of PRV from the E3 region, the gene encoding gD without any transcription control elements was first inserted into the transfer vector and rescued into pFPAV-300 by recombination in BJ 5183 (Fig. 2 a) . The desired recombinant virus was generated following transfection of ST cells with PacI-restricted pFPAV-300-gD. The presence of the gD gene in the genome was confirmed by restriction enzyme analysis. The SalI restriction pattern of DNA from PAV-3-gD differed from that of wild-type viral DNA. This was due to an internal SalI site in gp50, which resulted in the cleavage of the top band noticed in wild-type viral DNA into two smaller fragments (Fig. 3 a, lanes  4 and 5) . Southern blot analyses was performed on SalIrestricted full-length plasmids, which were used for manipulating the E3 region and the viral DNA with $#P-labelled gp50. The probe hybridized to only those fragments which were expected to contain the sequences from gD gene (Fig. 3 b, lanes  3 and 6) . The recombinant virus replicated in cells approximately to the same titres or a little less efficiently than wildtype PAV-3, indicating that these modifications to the genome had no dramatic effect on virus growth (see Fig. 6 ). Expression of gp50 by the recombinant virus was monitored by immunoprecipitation assays using monoclonal antibodies specific to the protein. Expression was seen only at 12 h postinfection and no protein could be detected after this time-point (Fig. 5) .
CAT gene expression from the right end of the genome
In HAV-5, a site upstream from the E4 promoter near the right end of the genome has been used to express foreign . Single-step growth curve for wild-type and recombinants of PAV-3. Confluent monolayers of VIDO R1 cells in six-well culture plates were inoculated with wild-type PAV-3 (j), PAV-3 E3 (), PAV-3 gD (#), PAV-3 CAT2 (U) or PAV-3 CAT6 (>) at an m.o.i. between 5 and 10. The production of infectious virus was monitored at various time-points post-infection by harvesting cells along with the supernatant, freezing and thawing three times and determining virus titres by infectivity assay (TCID 50 ) in microtitre plates.
genes (Saito et al., 1985 ; Makimura et al., 1996) . To test whether a similar site in PAV-3 could be used to express foreign genes, the CAT gene under the control of the SV40 immediate early promoter and SV40 poly(A) signal was introduced into the HpaI site located near the right end of the genome (Fig. 2 b) . The HindIII restriction patterns of the plasmids used to generate CAT gene viral recombinants and of the viruses DNA were analysed and were as expected (Fig. 4) . Southern blot analyses of the DNA from the plasmids and recombinant viruses with $#P-labelled CAT gene was performed. In all cases, the probe hybridized only to those fragments expected to carry the CAT gene sequences (Fig. 4 b, lanes 2, 3, 5 and 6). CAT activity in infected cells was monitored by an assay based on liquid scintillation counting of CAT reaction products. Low levels of CAT expression were seen early in infection and the levels of expression reached a peak at about 36 h post-infection (Fig. 7) . CAT gene expression was also monitored in human cell lines such as 293 and A549 cells, which are non-permissive to PAV-3. In these cell lines, low levels of CAT gene expression were seen 12 h postinfection and increased steadily afterwards. These two recombinant viruses replicated less efficiently than the wild-type virus in VIDO R1 cells (Fig. 6) .
Discussion
This is the first report on the development of PAV as an expression vector. The long-term objective of this work was to develop replication-competent PAV-3 as a gene transfer vector which could be used as a live viral delivery system to induce a mucosal immune response in pigs. Plasmid pFPAV-200, from which the viral genome can be excised, was constructed as described in Methods. The use of pFPAV-200 allows for rapid and relatively simple manipulation of the PAV genome. A number of such modifications carried out on pFPAV-200 were subsequently delivered into the viral genome. Extensive restriction enzyme analysis of pFPAV-200 after several rounds of amplification in E. coli DH5α revealed no detectable DNA rearrangements, indicating that the plasmid was stable. In contrast, HAV-5 DNA cloned into a single plasmid using the DNA extracted from baby rat kidney (BRK) cells was unstable (Bett et al., 1994) . This was attributed to long palindrome sequences created by head-to-tail joining of the ITRs. In our case, the left and right ITR sequences are separated from each other by a 2 kb sequence from pPolyIIsn, thus avoiding generation of palindromic sequences, which are more prone to rearrangements. The plasmid-derived viral DNA, when transfected into permissive cells, resulted in the generation of virus, indicating that the presence of a few extra nucleotides, resulting from digestion with PacI, at either end of the genome did not affect the infectivity of the DNA. Similar observations were made for the plasmid-derived viral DNAs of HAV-5 (Chartier et al., 1996) and BAV-3 (Zakhartchouk et al., 1998) .
Like any other icosahedral viral vector, adenoviruses have limited vector capacity : they can accommodate up to 105 % and 114 % of the wild-type genome lengths in HAV-5 (GhoshChoudhury et al., 1987) and ovine adenovirus (OAV) respectively (Xu et al., 1997) . The exact packaging capacity of PAV-3 is currently unknown. The genome size of PAV-3 is 34 494 bp so its capsid should be able to accommodate at least 1n7 kb of foreign DNA based on the 105 % packaging rule of HAV-5. With a 595 bp deletion made in the E3 region, a PAV-3-based replication-competent viral vector should be able to accommodate 2n3 kb of foreign DNA, which would cover the majority of structural genes. The 595 bp E3 deletion removes part of ORF2 and the complete ORF3 of the E3 region but leaves ORF1 intact. The results of insertional inactivation indicate that ORF1 in the E3 region of PAV-3 may be essential for virus replication. The deduced amino acid sequence of ORF1 showed significant identity with a 13n3 kDa putative E3 protein of canine adenovirus-2 (CAV-2) and a 12n5 kDa E3 protein of BAV-1 (Evans et al., 1998) . Recently, this ORF in BAV-1 was shown to be nonessential for virus replication (Evans et al., 1998) . Currently, we are looking into the role of this putative protein in PAV-3 replication. Recombinant PAV-3 carrying the GFP gene in the SnaBI site without any E3 deletion did not express the protein. This could be due to the fact that GFP was inserted into the region without any transcription control elements or that the initiation codon of GFP might not be the first ATG even if the GFP coding region was present in some of the transcripts generated from the region.
The gene encoding gD of PRV was inserted into the SnaBI site of a modified E3, which is located upstream of the L5 poly(A) signal. This insertion site was chosen in order to maintain the integrity of the L5 poly(A) signal and poly(A) site, which it shares with those of the E3 region ; also, this site is unique in the genome of PAV-3 (S. Reddy and others, unpublished) . Expression of gD was transient and could only be seen early in infection (12 h), indicating that expression from the region is temporally regulated. This is in contrast to recombinant BAV-3 expressing glycoprotein D (gD) of bovine herpesvirus 1 (BHV-1) from the E3 region, where expression was seen first at 24 h post-infection and continued throughout infection (Zachartchouk et al., 1998) . In both cases the foreign genes were inserted into the E3 region without any flanking regulatory sequences. The difference between the two recombinants was that the E3 region was completely deleted in BAV-3, whereas in PAV-3 only part of the E3 region could be deleted.
The unique SnaBI site of pFPAV-300 was cleaved allowing for targeting of the insert into the E3 region by homologous recombination. More than 90 % of the clones obtained were positive. It was reported earlier by Chartier et al. (1996) that the yields of recombinants were higher in BJ 5183 when the fulllength plasmid was linearized as close as possible to the centre of the targeted region. Similar observations were made when the CAT gene was cloned at a site near the right end of the genome of PAV-3 wherein the HpaI site was used to linearize the full-length plasmid. Other reasons for obtaining a higher percentage of recombinants could be due to phosphatase treatment of vectors following linearization and also the generation of blunt ends.
Recombinants of PAV-3 expressing the CAT gene replicated 2-3 logs less efficiently than wild-type PAV-3. This could be due to the close proximity of transcription control elements used in the expression cassette to the promoter of the E4 region, resulting in competitive suppression of the E4 promoter. Proteins produced from the E4 region play a major role in virus replication and the reduced levels of E4 proteins may result in low virus yields. The other reason could be insertional inactivation of some of the upstream transcription control elements of the E4 promoter as the site of insertion is just 77 nucleotides upstream of the TATA box of the E4 region.
In conclusion, we have adapted the E. coli recombination approach to develop a PAV-3-based expression system. With this method, the desired recombinant adenovirus was almost always obtained in a single experiment without any selection procedure. We have developed a full-length infectious clone of PAV-3, E3 deletion mutants and recombinants expressing PRV-gD from the E3 region and CAT gene from a site near the right end of the genome. Presently we are testing the pathogenicity and the ability of recombinant adenovirus expressing gD to induce a mucosal immune response in piglets.
